Outcomes and side effects after first-line treatment with combination therapies for kidney cancer
This report looked at the results from 4 studies comparing [...]
Role of nephrectomy for metastatic kidney cancer in the immunotherapy era
Three phase III clinical trials (Keynote 426, Checkmate 9ER and [...]
EIKCS 2021: Combination therapies for metastatic kidney cancer: Which Approach?
The use of combination therapies for the first-line treatment of [...]
Updated results from a trial with belzutifan for people with advanced kidney cancer
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, [...]
Atezolizumab plus bevacizumab for metastatic kidney cancer patients with disease progression on atezolizumab or sunitinib
A study published in European Urology this month looks at [...]
Association of immune-related adverse events and outcomes in kidney cancer
Previous studies have shown that cancer patients who experience immune-related [...]
Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer
This Practice Update interview with Dr Monty Pal from City [...]
ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer
Results from the phase 3 CLEAR study, presented at the [...]
ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer
A gene called MET codes for a protein called MET [...]
ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer
In a small phase 2 study presented at the virtual [...]
